Community Healthcare Trust vs. Sabra Health Care REIT: Which Real Estate Stock Is a Better Buy in 2026?

The article compares Community Healthcare Trust and Sabra Health Care REIT as 2026 income investments, highlighting Sabra’s larger scale, higher FY2025 revenue of $774.6 million, and stronger net income of $155.6 million versus Community Healthcare Trust’s $121.2 million revenue and $5.1 million net income. Sabra also offers a 6.41% dividend yield, but faces interest-rate and share-dilution concerns; Community Healthcare Trust has lower leverage at 1.2x debt-to-equity but weaker profitability and concentration risk. The piece is opinion-driven rather than news-driven, so near-term price impact should be limited.

Analysis

SBRA is the cleaner relative value if the goal is to own a healthcare landlord into 2026, but the more important point is that the market is still mispricing the duration of its cash flow stability versus its optics. Skilled nursing and senior housing are messy operating businesses, yet that mess also creates a higher bar for new supply and a slower competitive response, which should support occupancy and rent resets over the next 4-6 quarters if rates stop rising. CHCT’s niche looks safer on paper, but its smaller tenant base and regional concentration make it more vulnerable to one-off credit events that can overwhelm the apparent diversification benefit.

The second-order winner is likely not the highest-quality operator, but the landlord with enough scale to access capital cheaply and survive a prolonged financing freeze. That favors SBRA over CHCT because any acquisition market dislocation should widen the spread between public REIT funding costs and private market cap rates; the stronger balance sheet also gives SBRA more room to recycle assets opportunistically if transaction volume returns. WELL and VTR remain the competitive benchmarks, but if rate volatility persists, their premium multiples leave them more exposed to multiple compression than to fundamentals deterioration.

The consensus seems to assume the dividend is the whole story; that misses the setup where sentiment can improve faster than earnings. If the 10-year yield stabilizes, SBRA can re-rate quickly because the stock has already absorbed dilution and rate fears, while CHCT lacks a comparable catalyst and is more likely to stay range-bound. The main tail risk for SBRA is that managed senior housing margins get squeezed again by labor, which would turn the stock into a value trap; for CHCT, the bigger risk is an idiosyncratic tenant default that hits coverage before investors can diversify away the story.

Key Decisions for Investors

• Long SBRA / short CHCT for a 6-12 month relative-value trade: express the view that scale, dividend support, and capital access will matter more than niche quality; stop out if CHCT outperforms SBRA by >10% or if rates re-accelerate higher.
• Buy SBRA on weakness with a 3-6 month horizon; target a re-rating as rate fears fade, with upside driven more by multiple expansion than near-term FFO growth.
• Use WELL as a quality hedge against SBRA: long SBRA, short a smaller amount of WELL to isolate valuation mean reversion while limiting sector beta.
• If volatility stays elevated, sell cash-secured puts on SBRA at strikes 10-15% below spot to monetize elevated implied risk premia while waiting for the dividend.
• Avoid initiating a fresh long in CHCT until tenant credit and regional concentration risks are de-risked; the asymmetry is poorer because the stock lacks a near-term catalyst to offset single-tenant downside.